Sorrento Therapeutics Inc
Sorrento Therapeutics Inc logo
SRNE

Sorrento Therapeutics Inc (SRNE)

$2.167.46%

  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$2.06
Day's Range
$2.19
$1.15
52-Week Range
$9.99
1 month return29.52%
3 month return1.42%
1 year return73.84%
5 year return10.26%

Company Information

Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies ('G-MAB™library'), clinical stage immuno-cellular therapies ('CAR-T', 'DAR-T'), antibody-drug conjugates ('ADCs'), and clinical stage oncolytic virus ('Seprehvir®'). Sorrento is also developing potential coronavirus antiviral therapies and vaccines, including COVIDTRAP™, ACE-MAB™, COVI-MAB™, COVI-GUARD™, COVI-SHIELD™and COVI-CELL™. Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by its effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin ('RTX'), and ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX is completing a phase IB trial for intractable pain associated with cancer and a phase 1B trial in osteoarthritis patients. ZTlido® was approved by the FDA on February 28, 2018.
OrganizationSorrento Therapeutics Inc
CEOHenry Ji
IndustryHealth Technology

Analyst Recommendation

based on 8 analysts ratings

Buy
87%
Buy
12%
Hold
0%
Sell

Based on 8 Wall street analysts offering stock ratings for Sorrento Therapeutics Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 923.26%

Current

$2.15

Target

$22.0

Recommendation Trend

Based on 8 analyst

Current1M Ago3M Ago
Buy
7
7
7
Hold
1
1
1
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization
543.2M
Book Value
0.26
Dividend Share
0.0
Dividend Yield
0.0
Earnings Share
-1.45
PEG Ratio
-0.07
Wall Street Target Price
21.0

Valuation

Trailing PE0.0
Forward PE1.18
Price/Sales (ttm)
10.27
Price/Book (mrq)
7.47
Enterprise Value
698.6M
Enterprise Value/Revenue
13.21
Enterprise Value/Ebitda
0.0

Technicals

Beta
2.31
50 Day MA
2.27
200 Day MA
5.48

Institutional Holdings

State Street Corporation

8.73%

BlackRock Inc

5.6%

Vanguard Group Inc

4.09%

Geode Capital Management, LLC

1.28%

JPMorgan Chase & Co

0.85%

Northern Trust Corp

0.72%

Discover more

Frequently Asked Questions

What is Sorrento Therapeutics Inc share price today?

Can Indians buy Sorrento Therapeutics Inc shares?

How can I buy Sorrento Therapeutics Inc shares from India?

Can Fractional shares of Sorrento Therapeutics Inc be purchased?

What are the documents required to start investing in Sorrento Therapeutics Inc stocks?

What are today’s High and Low prices of Sorrento Therapeutics Inc?

What are today’s traded volumes of Sorrento Therapeutics Inc?

What is today’s market capitalisation of Sorrento Therapeutics Inc?

What is the 52 Week High and Low Range of Sorrento Therapeutics Inc?

How much percentage Sorrento Therapeutics Inc is down from its 52 Week High?

How much percentage Sorrento Therapeutics Inc is up from its 52 Week low?

What are the historical returns of Sorrento Therapeutics Inc?

Who is the Chief Executive Officer (CEO) of Sorrento Therapeutics Inc?